메뉴 건너뛰기




Volumn 31, Issue 10, 2013, Pages 1341-1347

Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: A randomized, phase III trial

(17)  Carrato, Alfredo a   Swieboda Sadlej, Anna b   Staszewska Skurczynska, Marzanna b   Lim, Robert c   Roman, Laslo d   Shparyk, Yaroslav e   Bondarenko, Igor f   Jonker, Derek J g   Sun, Yan h   De La Cruz, Jhony A i   Williams, J Andrew j   Korytowsky, Beata k   Christensen, James G j   Lin, Xun j   Tursi, Jennifer M j   Lechuga, Maria J j   Van Cutsem, Eric l  


Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PLACEBO; SUNITINIB;

EID: 84876089340     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.1930     Document Type: Article
Times cited : (120)

References (22)
  • 3
    • 33746805967 scopus 로고    scopus 로고
    • Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American intergroup trial
    • DOI 10.1200/JCO.2006.06.1317
    • Goldberg RM, Sargent DJ, Morton RF, et al: Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J Clin Oncol 24:3347-3353, 2006 (Pubitemid 46638888)
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.21 , pp. 3347-3353
    • Goldberg, R.M.1    Sargent, D.J.2    Morton, R.F.3    Fuchs, C.S.4    Ramanathan, R.K.5    Williamson, S.K.6    Findlay, B.P.7    Pitot, H.C.8    Alberts, S.9
  • 5
    • 42949149159 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
    • Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 20:2013-2019, 2008
    • (2008) J Clin Oncol , vol.20 , pp. 2013-2019
    • Saltz, L.B.1    Clarke, S.2    Díaz-Rubio, E.3
  • 9
    • 78650874372 scopus 로고    scopus 로고
    • SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
    • Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
    • (2003) Mol Cancer Ther , vol.2 , pp. 471-478
    • Abrams, T.J.1    Lee, L.B.2    Murray, L.J.3
  • 13
    • 84855168247 scopus 로고    scopus 로고
    • A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer
    • Starling N, Vázquez-Mazón F, Cunningham D, et al: A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Ann Oncol 23:119-127, 2012
    • (2012) Ann Oncol , vol.23 , pp. 119-127
    • Starling, N.1    Vázquez-Mazón, F.2    Cunningham, D.3
  • 14
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 15
    • 0018687930 scopus 로고
    • A multiple testing procedure for clinical trials
    • DOI 10.2307/2530245
    • O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979 (Pubitemid 10242750)
    • (1979) Biometrics , vol.35 , Issue.3 , pp. 549-556
    • O'Brien, P.C.1    Fleming, T.R.2
  • 16
    • 84876076798 scopus 로고    scopus 로고
    • Application of adaptive study designs: Phase II and III results from the cediranib (CED) HORIZON (HZ) II and III studies
    • abstr 3633∧
    • Wilson D, Hoff PM, Schmoll H, et al: Application of adaptive study designs: Phase II and III results from the cediranib (CED) HORIZON (HZ) II and III studies. J Clin Oncol 29:254s, 2011 (suppl; abstr 3633∧)
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Wilson, D.1    Hoff, P.M.2    Schmoll, H.3
  • 17
    • 79956334386 scopus 로고    scopus 로고
    • Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma
    • Hecht JR, Trarbach T, Hainsworth JD, et al: Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29:1997-2003, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 1997-2003
    • Hecht, J.R.1    Trarbach, T.2    Hainsworth, J.D.3
  • 18
    • 67650996205 scopus 로고    scopus 로고
    • Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer
    • Sobrero A, Ackland S, Clarke S, et al: Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77:113-119, 2009
    • (2009) Oncology , vol.77 , pp. 113-119
    • Sobrero, A.1    Ackland, S.2    Clarke, S.3
  • 20
    • 75749096309 scopus 로고    scopus 로고
    • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
    • Kopetz S, Hoff PM, Morris JS, et al: Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:453-459, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 453-459
    • Kopetz, S.1    Hoff, P.M.2    Morris, J.S.3
  • 21
    • 79956297102 scopus 로고    scopus 로고
    • Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma
    • Van Cutsem E, Bajetta E, Valle J, et al: Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29:2004-2010, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 2004-2010
    • Van Cutsem, E.1    Bajetta, E.2    Valle, J.3
  • 22
    • 77953033291 scopus 로고    scopus 로고
    • Relationship between exposure to sunitinib and efficacy and tolerability end points in patients with cancer: Results of a pharmacokinetic/pharmacodynamic meta-analysis
    • Houk BE, Bello CL, Poland B, et al: Relationship between exposure to sunitinib and efficacy and tolerability end points in patients with cancer: Results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66:357-371, 2010
    • (2010) Cancer Chemother Pharmacol , vol.66 , pp. 357-371
    • Houk, B.E.1    Bello, C.L.2    Poland, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.